LY3954068 / Eli Lilly - LARVOL DELTA

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Eli Lilly and Company | N=32 ➔ 48

Enrollment change • First-in-human • Alzheimer's Disease • CNS Disorders

DEVELOPMENT OF LY3954068, AN INTRATHECALLY ADMINISTERED MICROTUBULE-ASSOCIATED PROTEIN TAU (MAPT) SMALL INTERFERENCE RNA (SIRNA) FOR ALZHEIMER'S DISEASE (ADPD 2025) - P1 | "Conclusions LY3954068 is a potent siRNA with specificity for human MAPT mRNA, effectively suppressing tau protein translation. This promising therapeutic approach for tauopathies is currently being evaluated in a clinical trial in patients with early symptomatic AD."

Alzheimer's Disease • CNS Disorders • MAPT

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Eli Lilly and Company | N=60 ➔ 32

Enrollment change • Alzheimer's Disease • CNS Disorders

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Alzheimer's Disease • CNS Disorders